Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 23, 2017

NewStem develops new diagnostic kit to predict chemotherapy resistance

NewStem, a spinoff of Israeli Hebrew University of Jerusalem’s technology-transfer firm called Yissum Research Development, is developing a new diagnostic kit to predict resistance to chemotherapy.

NewStem, a spinoff of Israeli Hebrew University of Jerusalem’s technology-transfer firm called Yissum Research Development, is developing a new diagnostic kit to predict resistance to chemotherapy.

Based on the research of human haploid pluripotent stem cells (HHPSCs) by Azrieli Centre for Stem Cells and Genetic Research professor Nissim Benvenisty, the kit will employ a new technology developed by NewStem.

Chemotherapy is reported to usually result in primary and/or secondary resistance to the drugs.

The differentiation capacity of pluripotent stem cells makes them useful for the examination of mutated genes’ influence on different cells, physiological processes and drug responses.

Due to their diploid characteristic, the generation of these cells with two copies of mutated genes is considered to be difficult.

NewStem’s new technology can be used to address this concern, as it allows the generation of fully functional haploid stem cells.

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

The firm holds the intellectual property, reagents and experience required for the haploid pluripotent stem cell (HPSC) isolation, differentiation, genetic manipulation, immunogenicity and tumorigenicity.

"The haploid stem cells we're developing have the potential to change the face of medical research as they hold a pivotal role in regenerative medicine, disease therapy and cancer research."

NewStem chief executive officer Ayelet Dilion-Mashiah said: "The haploid stem cells we're developing have the potential to change the face of medical research as they hold a pivotal role in regenerative medicine, disease therapy and cancer research.

“NewStem is the only company worldwide to develop novel products based on this paradigm-changing proprietary technology, which we acquired under an exclusive licence from Yissum.

"We are currently in the process of raising funds for our research development and regulatory activities."

The availability of a broad library of HPSCs with various mutations and genetic makeups is expected to allow NewStem to develop diagnostic kits for personalised medication, as well as therapeutic and reproductive products.


Image: Haploid cell on the left (with 23 chromosomes); Diploid cell on the right (with 46 chromosomes). Photo: courtesy of PRNewsfoto/Yissum.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU